{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:44:52Z","timestamp":1792806292016,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Migraine frequency increases after the cessation of successful preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs). In this study, we aimed to evaluate the course of migraine after treatment resumption.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with migraine, who started treatment with the same CGRP(-R) mAb after a three-month drug holiday were included in this analysis. We collected headache data at four prospective visits: 1) during the four weeks before the initial mAb treatment (baseline); 2) during the four weeks before the last mAb injection; 3) in weeks 13\u201316 of the drug holiday; 4) in weeks 9\u201312 after treatment restart. Outcomes were the changes in monthly migraine days (MMD), monthly headache days (MHD), monthly days with acute medication use (AMD) and Headache Impact Test-6 (HIT-6) scores across the observation period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study included 39 patients (erenumab <jats:italic>n<\/jats:italic>\u2009=\u200916; galcanezumab\/ fremanezumab <jats:italic>n<\/jats:italic>\u2009=\u200923). MMD decreased from 12.3\u2009\u00b1\u20096.3 at the end of the drug holiday to 7.8\u2009\u00b1\u20095.5 three months after treatment restart (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). The improvement after treatment resumption was similar to the response in the initial treatment period (baseline: 12.3\u2009\u00b1\u20096.3 MMD vs. 7.5\u2009\u00b1\u20095.2 MMD before treatment interruption). MHD and AMD showed a significant improvement after treatment restart. HIT-6 scores decreased, indicating a diminished impact of headache on everyday life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Reinitiation of treatment with CGRP(-R) mAbs after a drug holiday leads to a significant reduction of migraine frequency and medication use as well as improvement in quality of life.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01417-9","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:04:41Z","timestamp":1648602281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience"],"prefix":"10.1186","volume":"23","author":[{"given":"Bianca","family":"Raffaelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Terhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Mecklenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Neeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Hendrik","family":"Overeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Steinicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"issue":"12","key":"1417_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/14712598.2019.1671350","volume":"19","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli B, Neeb L, Reuter U (2019) Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 19(12):1307\u20131317","journal-title":"Expert Opin Biol Ther"},{"issue":"22","key":"1417_CR2","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132","journal-title":"N Engl J Med"},{"issue":"6","key":"1417_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology 16(6):425\u2013434","journal-title":"The Lancet Neurology"},{"issue":"19","key":"1417_CR4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"issue":"22","key":"1417_CR5","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"9","key":"1417_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"24","key":"1417_CR7","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221","journal-title":"Neurology"},{"issue":"9","key":"1417_CR8","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ (2020) Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60(9):2014\u20132025","journal-title":"Headache"},{"issue":"1","key":"1417_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21(1):84","journal-title":"J Headache Pain"},{"key":"1417_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"11","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A et al (2020) erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 11:417","journal-title":"Front Neurol"},{"issue":"1","key":"1417_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61","journal-title":"J Headache Pain"},{"issue":"13","key":"1417_CR12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/03331024211046617","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40(13):1511\u20131522. https:\/\/doi.org\/10.1177\/03331024211046617","journal-title":"Cephalalgia"},{"issue":"10","key":"1417_CR13","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferr\u00fas","year":"2021","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268(10):3789\u20133798","journal-title":"J Neurol"},{"issue":"1","key":"1417_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6","journal-title":"J Headache Pain"},{"issue":"11\u201312","key":"1417_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein AR, Agosti R, Gobbi C, Fl\u00fcgel D, Schankin CJ, Viceic D et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia 41(11\u201312):1181\u20131186","journal-title":"Cephalalgia"},{"issue":"8","key":"1417_CR16","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","volume":"42","author":"E De Matteis","year":"2021","unstructured":"De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA et al (2021) Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci 42(8):3297\u20133303","journal-title":"Neurol Sci"},{"key":"1417_CR17","doi-asserted-by":"publisher","unstructured":"Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, et al ( 2021)\u00a0Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia 3331024211046617. https:\/\/doi.org\/10.1111\/ene.15260","DOI":"10.1111\/ene.15260"},{"issue":"8","key":"1417_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2013974","journal-title":"Qual Life Res"},{"issue":"1","key":"1417_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain 22(1):154","journal-title":"J Headache Pain"},{"issue":"6","key":"1417_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/head.13508","volume":"59","author":"VL Stauffer","year":"2019","unstructured":"Stauffer VL, Wang S, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK (2019) Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase 3 trials. Headache 59(6):834\u2013847","journal-title":"Headache"},{"key":"1417_CR21","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of Anti-CGRP antibodies discontinuation and reinitiation in resistant chronic migraine. Eur J Neurol"},{"issue":"12","key":"1417_CR22","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1176\/ajp.149.12.1727","volume":"149","author":"RM Post","year":"1992","unstructured":"Post RM, Leverich GS, Altshuler L, Mikalauskas K (1992) Lithium-discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 149(12):1727\u20131729","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1417_CR23","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1176\/ajp.151.10.1522","volume":"151","author":"M Bauer","year":"1994","unstructured":"Bauer M (1994) Refractoriness induced by lithium discontinuation despite adequate serum lithium levels. Am J Psychiatry 151(10):1522","journal-title":"Am J Psychiatry"},{"issue":"9","key":"1417_CR24","first-page":"401","volume":"144","author":"F Oostervink","year":"2000","unstructured":"Oostervink F, Nolen WA, Hoenderboom AC, Kupka RW (2000) Risk of inducing resistance upon stopping and restarting lithium after long-term usage. Ned Tijdschr Geneeskd 144(9):401\u2013404","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"6","key":"1417_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10673220601070039","volume":"14","author":"B Appleby","year":"2006","unstructured":"Appleby B, Wise T, Isaac A (2006) A case of refractoriness to lithium therapy following its discontinuation in a previously responsive patient. Harv Rev Psychiatry 14(6):330\u2013332","journal-title":"Harv Rev Psychiatry"},{"issue":"1","key":"1417_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jad.2011.09.021","volume":"140","author":"RM Post","year":"2012","unstructured":"Post RM (2012) Acquired lithium resistance revisited: discontinuation-induced refractoriness versus tolerance. J Affect Disord 140(1):6\u201313","journal-title":"J Affect Disord"},{"issue":"1","key":"1417_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s10194-020-01211-5","volume":"22","author":"JM Cohen","year":"2021","unstructured":"Cohen JM, Ning X, Kessler Y, Rasamoelisolo M, Campos VR, Seminerio MJ et al (2021) Immunogenicity of biologic therapies for migraine: a review of current evidence. J Headache Pain 22(1):3","journal-title":"J Headache Pain"},{"issue":"4","key":"1417_CR28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644\u2013655","journal-title":"Headache"},{"issue":"9","key":"1417_CR29","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/head.13157","volume":"57","author":"JM Woolley","year":"2017","unstructured":"Woolley JM, Bonafede MM, Maiese BA, Lenz RA (2017) Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache 57(9):1399\u20131408","journal-title":"Headache"},{"issue":"11","key":"1417_CR30","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0333102419854082","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA et al (2019) Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39(11):1455\u20131464","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01417-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:04:49Z","timestamp":1648602289000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01417-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01417-9","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Charit\u00e9 Ethical Committee (EA1\/274\/19). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BR reports research grants from Novartis, and personal fees from Allergan, Hormosan, Lilly, Novartis, and Teva. MT reports personal fees from TEVA. JM reports personal fees from Novartis. AS reports personal fees from TEVA and Novartis. LN has contributed to the advisory boards of Hormosan, Lilly, Novartis, and Teva, and received speaking fees from Allergan, Bial, Hormosan, Lilly, Novartis, and Teva; LN received research funding from Deutsche Zentrum f\u00fcr Luft- und Raumfahrt. UR received honoraria for consulting and lectures from Amgen, Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis, electroCore, Medscape, StreaMedUp, and Teva. UR received research funding from the German Federal Ministry of Education and Research and Novartis. The other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}